ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 0172

Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review

Teresa Xiao1, Namrata Singh2 and Pankti Reid3, 1University of Chicago, Chicago, IL, 2University of Washington, Bellevue, WA, 3University of Chicago Medical Center, Chicago, IL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: Clinical practice guidelines, Health Care, Oncology, population studies, risk factors

Session Information

Date: Sunday, October 26, 2025

Title: (0145–0174) Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: There is minimal guidance on specific cancer screening practices for rheumatic diseases (RDs) other than for myositis. The aim of this scoping review was to evaluate the available evidence on the risk of cancer for various RDs and associated risk factors.

Methods: We evaluated cancer associations and risk factors associated with incident cancer development for key systemic RDs: RA, SSc, and SS. We conducted a comprehensive literature search via PubMed to identify relevant publications with the following search terms: “systemic sclerosis” or “Sjogren’s disease” or “rheumatoid arthritis” and “cancer” or “malignancy” or “risk” or “risk factors.” Data for cancer associations was limited to meta-analyses. Associated risk factors for incident cancer were obtained from meta-analyses and retrospective/prospective observational studies.

Results: We reviewed 19 manuscripts: 6 for cancer associations and 13 for risk factors. There were 3 meta-analyses for RA, 3 for SSc, and 1 for SS that reflected standardized incidence ratios (SIRs) for cancer. SS had 6 publications describing risk factors associated with cancer, followed by SSc (4) and RA (3). SSc was most commonly associated with liver cancer or lung cancer, RA with lymphoma and SS with hematologic malignancies, in particular non-Hodgkin’s lymphoma (Table 1). Incident cancer risk for SSc was most commonly associated with anti-transcriptional intermediary factor 1 (TIF-1γ) positivity (Table 1). RF and anti-CCP positivity were associated with lung cancer for patients with RA (Table 1). SS literature identified the highest cancer association with low complement levels and lymphocytopenia (Table 1). For RA and SSc, interstitial lung disease (ILD) was identified for both as a risk factor associated with malignancy.

Conclusion: RA, SSc, and SS are uniquely associated with different cancers. High-powered prospective studies to inform evidence-based, expert driven screening guidelines are needed to identify effectiveness of various cancer screening recommendations and guide appropriate clinical care.

Supporting image 1Table 1. Cancer associations and risk factors for incident cancer in SSc, RA, and SS.

Supporting image 2Figure 1. Cancer screening in rheumatic diseases.


Disclosures: T. Xiao: None; N. Singh: None; P. Reid: AbbVie/Abbott, 1, Amgen, 6, Mustang Bio, 1, UCB, 1.

To cite this abstract in AMA style:

Xiao T, Singh N, Reid P. Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/cancer-screening-for-patients-with-rheumatic-diseases-a-scoping-review/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cancer-screening-for-patients-with-rheumatic-diseases-a-scoping-review/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology